<a href="https://laohu8.com/S/EDSA">Edesa Biotech</a> Inc. reports FY research and development expenses of USD 3.7 million, up 27%
Edesa Biotech Inc. reported a net loss of USD 7.2 million, or USD 1.27 per common share, for the full year ended September 30, 2025. This compares to a net loss of USD 6.2 million, or USD 1.93 per common share, for the previous year. As of September 30, 2025, Edesa Biotech Inc. held cash and cash equivalents of USD 10.8 million and reported working capital of USD 10.4 million. General and administrative expenses for the period increased to USD 4.2 million, primarily due to higher noncash share-based compensation. Total other income for the year was USD 0.7 million, mainly reflecting a decrease in interest income. Subsequent to the fiscal year end, the company raised USD 3.4 million in net proceeds from the sale of common shares under an at-the-market offering program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601061) on December 12, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。